Rani Therapeutics Holdings, Inc.
RANI
$1.05
-$0.05-4.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 42.12% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.12% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 42.12% | -- | -- | -- | -- |
| SG&A Expenses | -6.87% | -28.27% | -21.98% | -12.92% | -6.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.55% | -38.49% | -16.12% | -13.18% | -8.65% |
| Operating Income | 24.09% | 38.49% | 16.12% | 14.40% | 16.30% |
| Income Before Tax | 42.28% | 37.79% | 15.99% | 13.81% | -11.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.28% | 37.79% | 15.99% | 13.81% | -11.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -118.17% | -57.87% | -30.87% | -24.97% | -2.62% |
| Net Income | -15.18% | 20.21% | 1.66% | 2.93% | -26.05% |
| EBIT | 24.09% | 38.49% | 16.12% | 14.40% | 16.30% |
| EBITDA | 23.95% | 39.05% | 16.33% | 14.68% | 16.88% |
| EPS Basic | 74.41% | 50.47% | 29.17% | 24.43% | 0.15% |
| Normalized Basic EPS | -98.66% | 24.64% | 0.44% | 0.27% | 68.27% |
| EPS Diluted | 48.63% | 50.47% | 29.17% | 24.43% | 0.15% |
| Normalized Diluted EPS | -98.66% | 24.64% | 0.44% | 0.27% | 68.27% |
| Average Basic Shares Outstanding | 350.38% | 61.06% | 38.82% | 28.45% | 26.23% |
| Average Diluted Shares Outstanding | 350.38% | 61.06% | 38.82% | 28.45% | 26.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |